Physician profile
Manuel Mercado
NPI 1316919228
$13,459.73
in general payments reported to CMS, 2019-2025
32 companies · $2,339 in 2025
The $2,339 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,735 · 2020: $2,216 · 2021: $2,228 · 2022: $1,455 · 2023: $2,019 · 2024: $1,467 · 2025: $2,339.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,720 · Education: $106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,720.08 |
| Education | $105.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,698.79 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $1,559.05 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $1,502.46 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $1,271.35 | 2019-2025 | |
| Abbvie INC. | $1,187.80 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $949.61 | 2019-2024 | Xarelto |
| Sanofi-Aventis U.S. LLC | $769.78 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $713.20 | 2019-2025 | Jardiance, Synjardy |
| Astrazeneca Pharmaceuticals LP | $686.44 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Astellas Pharma US INC | $494.56 | 2019-2023 | Myrbetriq |
| Otsuka America Pharmaceutical, INC. | $479.85 | 2023-2025 | Rexulti |
| Merck Sharp & Dohme LLC | $321.44 | 2019-2023 | Verquvo, Steglatro, Belsomra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $268.83 | 2019-2025 | Xifaxan |
| Amgen INC. | $243.71 | 2019-2025 | Repatha, Otezla, Otezla |
| Amarin Pharma, INC. | $241.30 | 2019-2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $211.63 | 2019-2020 | |
| Abbott Laboratories | $168.84 | 2022-2025 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $113.55 | 2020-2024 | |
| Phathom Pharmaceuticals, INC. | $108.24 | 2025 | Voquezna |
| Ironwood Pharmaceuticals, INC | $84.97 | 2023-2024 | Linzess |
| Bayer Healthcare Pharmaceuticals INC. | $79.55 | 2022-2025 | |
| Exact Sciences Corporation | $50.89 | 2024 | Cologuard Collection Kit |
| Lundbeck LLC | $46.37 | 2025 | Rexulti |
| Radius Health, INC. | $38.48 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $34.13 | 2025 | Gemtesa |
| Corium, LLC | $23.42 | 2023 | Adlarity |
| Paratek Pharmaceuticals, INC. | $23.02 | 2025 | Nuzyra |
| Kowa Pharmaceuticals America, INC. | $21.52 | 2025 | Zoryve |
| Esperion Therapeutics, INC. | $20.82 | 2024 | Nexletol |
| Redhill Biopharma INC. | $19.69 | 2021 | |
| Ucb, INC. | $14.50 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $11.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manuel Mercado listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.